Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase ½ dose escalation and expansion trial - El-Khoueiry, A B; Sangro, B; Yau, T (Lancet, 2017)
et al.